Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Less than $10/month! Get more Watchlists, Portfolios, Custom Views and Chart Templates with Barchart Plus. FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or
Faster, Cleaner, Better.

Revolution Medicines Inc (RVMD)

Revolution Medicines Inc (RVMD)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Market News and Commentary

This Oncology Stock Just Hit New All-Time Highs

Valued at $15 billion, Revolution Medicines (RVMD) is a clinical-stage oncology company. It is focused on developing targeted therapies for RAS-addicted cancers, which stem from mutations in RAS proteins. 

I found today’s Chart of the Day by using Barchart’s powerful screening functions to sort for stocks with the highest technical buy signals; superior current momentum in both strength and direction; and a Trend Seeker “buy” signal. I then used Barchart’s Flipcharts feature to review the charts for consistent price appreciation. RVMD checks those boxes. Since the Trend Seeker signaled a new “Buy” on Sept. 2, the stock has gained 96.53%.

Fundamentals

See More
  • Market Capitalization, $K 15,171,755
  • Shares Outstanding, K 193,320
  • Annual Sales, $ 0 K
  • Annual Income, $ -600,090 K
  • EBIT $ -1,037 M
  • EBITDA $ -1,070 M
  • 60-Month Beta 0.96
  • Price/Sales N/A
  • Price/Cash Flow N/A
  • Price/Book 9.09

Options Overview Details

View History
  • Implied Volatility 53.38% (+0.79%)
  • Historical Volatility 31.19%
  • IV Percentile 71%
  • IV Rank 37.10%
  • IV High 80.37% on 04/08/25
  • IV Low 37.46% on 09/18/25
  • Expected Move (DTE 14) 6.93 (8.70%)
  • Put/Call Vol Ratio 0.08
  • Today's Volume 525
  • Volume Avg (30-Day) 964
  • Put/Call OI Ratio 0.33
  • Today's Open Interest 48,235
  • Open Int (30-Day) 43,800
  • Expected Range 72.71 to 86.57

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 22 analysts offering recommendations.
Earnings Estimates - Current Qtr 12/31/25
See More
  • Average Estimate -1.60
  • Number of Estimates 11
  • High Estimate -1.45
  • Low Estimate -1.69
  • Prior Year -1.12
  • Growth Rate Est. (year over year) -42.86%

Price Performance

See More
Period Period Low Period High Performance
1-Month
58.91 +35.18%
on 11/07/25
79.82 -0.22%
on 12/05/25
+20.30 (+34.21%)
since 11/05/25
3-Month
39.73 +100.45%
on 09/10/25
79.82 -0.22%
on 12/05/25
+39.14 (+96.64%)
since 09/05/25
52-Week
29.17 +173.02%
on 04/07/25
79.82 -0.22%
on 12/05/25
+32.34 (+68.37%)
since 12/05/24

Most Recent Stories

More News
This Oncology Stock Just Hit New All-Time Highs

Revolution Medicines (RVMD) is trading at fresh all-time highs. RVMD exhibits strong technical momentum with a 100% technical “Buy” opinion from Barchart. Shares are up nearly 60% over the past year....

RVMD : 79.64 (+1.48%)
Revolution Medicines Reports Third Quarter 2025 Financial Results and Update on Corporate Progress

Company is winding down global enrollment for the RASolute 302 clinical trial studying daraxonrasib in patients with previously treated PDAC and remains on track for data readout in 2026 Company has initiated...

RVMD : 79.64 (+1.48%)
Revolution Medicines to Participate in November 2025 Investor Conferences

REDWOOD CITY, Calif., Nov. 04, 2025 (GLOBE NEWSWIRE) -- Revolution Medicines, Inc. (Nasdaq: RVMD), a late-stage clinical oncology company developing targeted therapies for patients with RAS-addicted...

RVMD : 79.64 (+1.48%)
Revolution Medicines to Report Financial Results for Third Quarter 2025 After Market Close on November 5, 2025

REDWOOD CITY, Calif., Oct. 29, 2025 (GLOBE NEWSWIRE) -- Revolution Medicines, Inc. (Nasdaq: RVMD), a late-stage clinical oncology company developing targeted therapies for patients with RAS-addicted...

RVMD : 79.64 (+1.48%)
Revolution Medicines’ RAS(ON) Multi-Selective Inhibitor Daraxonrasib Granted U.S. FDA Orphan Drug Designation in Pancreatic Cancer

REDWOOD CITY, Calif., Oct. 27, 2025 (GLOBE NEWSWIRE) -- Revolution Medicines, Inc. (Nasdaq: RVMD), a late-stage clinical oncology company developing targeted therapies for patients with RAS-addicted...

RVMD : 79.64 (+1.48%)
Revolution Medicines to Present Updated Elironrasib Safety and Efficacy Data in Patients with KRAS G12C Non-Small Cell Lung Cancer Following Treatment with a KRAS(OFF) G12C Inhibitor

REDWOOD CITY, Calif., Oct. 22, 2025 (GLOBE NEWSWIRE) -- Revolution Medicines, Inc. (Nasdaq: RVMD), a late-stage clinical oncology company developing targeted therapies for patients with RAS-addicted...

RVMD : 79.64 (+1.48%)
Revolution Medicines Awarded Voucher for Daraxonrasib (RMC-6236) Under FDA Commissioner's National Priority Voucher Pilot Program

REDWOOD CITY, Calif., Oct. 16, 2025 (GLOBE NEWSWIRE) -- Revolution Medicines, Inc. (Nasdaq: RVMD), a late-stage clinical oncology company developing targeted therapies for patients with RAS-addicted...

RVMD : 79.64 (+1.48%)
Revolution Medicines Announces Key Leadership Additions, including Alan Sandler, M.D. as Chief Development Officer

REDWOOD CITY, Calif., Sept. 29, 2025 (GLOBE NEWSWIRE) -- Revolution Medicines, Inc. (Nasdaq: RVMD), a late-stage clinical oncology company developing targeted therapies for patients with RAS-addicted...

RVMD : 79.64 (+1.48%)
Stocks Climb to Record Highs on the Outlook for Fed Rate Cuts

The S&P 500 Index ($SPX ) (SPY ) on Thursday closed up +0.85%, the Dow Jones Industrials Index ($DOWI ) (DIA ) closed up +1.36%, and the Nasdaq 100 Index ($IUXX ) (QQQ ) closed up +0.60%. September E-mini...

AMAT : 268.00 (-0.53%)
CELH : 42.06 (-1.41%)
RCAT : 8.02 (-3.61%)
DHI : 158.62 (-1.31%)
RNA : 71.63 (+0.13%)
OXM : 40.81 (+2.59%)
BLDR : 110.01 (-0.90%)
$IUXX : 25,692.05 (+0.43%)
ASML : 1,099.47 (-0.96%)
ZNH26 : 112-165s (-0.18%)
ESZ25 : 6,878.25s (+0.17%)
PHM : 126.99 (-0.70%)
Stocks Rally and Bond Yields Fall on Fed Rate Cut Hopes

The S&P 500 Index ($SPX ) (SPY ) today is up +0.66%, the Dow Jones Industrials Index ($DOWI ) (DIA ) is up +1.21%, and the Nasdaq 100 Index ($IUXX ) (QQQ ) is up +0.47%. September E-mini S&P futures (ESU25...

AMAT : 268.00 (-0.53%)
CELH : 42.06 (-1.41%)
RCAT : 8.02 (-3.61%)
DHI : 158.62 (-1.31%)
RNA : 71.63 (+0.13%)
OXM : 40.81 (+2.59%)
BLDR : 110.01 (-0.90%)
$IUXX : 25,692.05 (+0.43%)
ASML : 1,099.47 (-0.96%)
ZNH26 : 112-165s (-0.18%)
OXY : 42.43 (-0.56%)
ESZ25 : 6,878.25s (+0.17%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 100% Buy and ranks in the Top 1% of all short term signal directions.

Long term indicators fully support a continuation of the trend.

Relative Strength is above 80%. The market is in extreme overbought territory. Beware of a trend reversal.

See More Share

Business Summary

Revolution Medicines Inc. is a clinical-stage oncology company. It is focused on developing targeted therapies to inhibit elusive frontier targets within notorious cancer pathways. Revolution Medicines Inc. is based in CA, United States.

See More

Key Turning Points

3rd Resistance Point 82.27
2nd Resistance Point 81.04
1st Resistance Point 80.34
Last Price 79.64
1st Support Level 78.42
2nd Support Level 77.19
3rd Support Level 76.49

See More

52-Week High 79.82
Last Price 79.64
Fibonacci 61.8% 60.47
Fibonacci 50% 54.49
Fibonacci 38.2% 48.52
52-Week Low 29.17

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.
Free Barchart Webinar